期刊
ONCOGENE
卷 26, 期 25, 页码 3603-3613出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1210376
关键词
rituximab; R-CHOP; follicular lymphoma; diffuse large B-cell lymphoma; monoclonal antibodies
Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma ( FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients. Non-comparative studies have shown an activity in all other lymphomas. Because of its high activity and low toxicity ratio, rituximab has transformed the outcome of patients with B-cell lymphoma. A combination of rituximab plus chemotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL. Some patients are refractory to rituximab but the precise mechanisms of this refractoriness are not understood.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据